// App-Quantinova.ai

841 : A Phase II Study to Assess the Sustained Response Off Treatment in Patients with ITP Receiving Eltrombopag, Who Had a Previous Insufficient Response to Corticosteroids (TAPER): A Recruitment Update

Researchers

Presenter

  • Nichola Cooper

Principal Investigators

  • Waleed Ghanima

  • Jens Haenig

  • James Lee

  • Masiur Rahman

  • Francesco Zaja

Medical Centers

  • Hammersmith Hospital, Imperial College, London, United Kingdom

  • Department of Medicine, Vestfold Hospital Trust, Tønsberg, Norway

  • Novartis AG, Basel, Switzerland

  • Novartis Pharmaceutical Corporation, East Hanover, NJ

  • IQVIA, Kirkland, Quebec, Canada

  • Department of Medical Surgical and Health Sciences U.C.O. Medicina Clinica, University of Trieste, Trieste, Italy

Locations

  • United Kingdom

  • Norway

  • Switzerland

  • United States

  • Canada

  • Italy

Companies

  • Novartis AG

Study Components

Therapeutic Area

  • Infectious Diseases (ID)

Disease

  • Immune thrombocytopenia

  • Coronavirus disease

Biomarkers

  • N/A

Drug/Treatment

  • Eltrombopag

Outcome

  • N/A

Study Design

  • Open Label

  • Single Arm

  • Prospective

Phase

  • II

Study Id's

  • NCT02402998

  • NCT03524612

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved